Transdermal Drug Delivery System Market - Expected Revenue Growth in Near Future

Overview of This Study:

The study involved four major activities to estimate the current size for Transdermal Drug Delivery System Market. Exhaustive secondary research was done to collect information about the market, peer markets, and the parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chain through primary research. Thirdly, both top-down and bottom-up approaches were employed to estimate the complete market size. Finally, the market breakdown and data triangulation was used to estimate the market size of segments and subsegments.

Projected Surge in Revenue Generation:

The transdermal drug delivery system market is expected to reach USD 7.1 billion by 2023 from an estimated USD 5.7 billion in 2018, at a CAGR of 4.5% during the forecast period.

Market Size Estimation:

Top-down and bottom-up approaches were used to validate the size of the transdermal drug delivery systems market and estimate the size of other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

# The key players in the industry and markets have been identified through extensive secondary research.
# The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
# All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203190114

Recent Developments:

# In January 2018, Hisamitsu Pharmaceutical (Japan) launched ALLESAGA TAPE in the Japanese market.

# In July 2018, UCB (Belgium) received the Import Drug License (IDL) for its transdermal rotigotine patch—NEUPRO from the China Food and Drug Administration (CFDA).

# In August 2018, Luye Pharma (China) signed an agreement with Bayer AG (Switzerland) to acquire the global rights to the Apleek contraceptive transdermal patch

End Users:

Home care settings segment is expected to grow at the fastest rate during the forecast period

On the basis of end users, the transdermal drug delivery systems market is segmented into home care settings and hospitals & clinics. The home care settings segment is expected to grow at a higher CAGR during the forecast period. The high growth in this segment can be attributed to the increase in self-administration of medication at home, rapid growth in the geriatric population across the globe, and the growing need for cost-effective drug administration.

Geographical Growth Dynamics:

North America is expected to hold the largest market share during the forecast period

North America is one of the major revenue generating regions in the transdermal drug delivery systems market. The transdermal drug delivery systems market in the region is driven by the rising prevalence of targeted diseases (such as chronic pain, central nervous system disorders, and cardiovascular diseases) in the region, the increasing use of contraceptives, and the increasing number of research activities related to transdermal drug delivery systems.

Key Questions addressed by the report:

# Which are the key players in the market and how intense is the competition?
# Emerging countries have immense opportunities for the growth of transdermal drug delivery systems market, will this scenario continue?
# Which product market will dominate in future?
# What does the future look like for transdermal drug delivery systems?
# What are the challenges hindering the adoption of transdermal drug delivery systems?

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=203190114